Connect with us
After a relatively lackluster 2021, Amgen was looking for a second wind. The laboratory was only able to survive last year thanks to its collaboration with...
The French pharmaceutical group Sanofi explained that the price expectations of the target did not match its criteria. Some analysts had a mixed opinions on this...
Amgen's AMG 510 was a highlight at the 2019 American Society of Clinical Oncology meeting.
Teva initially got the chance to launch its drug called fremanezumab before Aimovig, but the opportunity slipped away when there was a delay in its FDA...